Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Steba Biotech

Status and phase: Terminated; Phase 2

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: WST11

Study type: Interventional

Funder types: Other

Identifiers

NCT00974662

CLIN903 LCM201

Details and patient eligibility

About

The aim of this study is to determine the dose of WST11 and light energy necessary to obtain desobstruction of the bronchial lumen using Vascular Targeted Photodynamic therapy in obstructive Non-Small Cell Lung Cancer.

Full description

This study is designed as a multicentre, exploratory phase IIa, open label, single intravenous (IV) dose, escalating treatment regimen (Treatment regimen = a single dose of WST11 associated with a particular laser light energy) with a one month follow-up.

Six escalating treatment regimens will be followed: 3 WST11 doses (5 mg/kg; 7.5 mg/kg and 10 mg/kg) combined with 2 light energies (200 Joules/cm and 300 Joules/cm)

The patient will be treated under local anesthesia. The light is produced using a specific laser at a wavelength of 753 nm at a fixed power of 250 mW/cm and locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven lung cancer
• Inoperable
• Non-Small Cell Cancer
• Partial or total bronchial obstruction responsible for functional signs
• T1 to T4, N0-N3, M0-M1
• Patients with functional signs: hemoptysis, infection, cough and, above all, dyspnea
• Contralateral metastases not representing a contraindication insofar as they do not represent a risk of impairment of respiratory function during treatment
• The Karnofsky index should be greater than or equal to 40
• Patients should agree to and tolerate repeated bronchial endoscopy (a disadvantage of all endoscopic treatments)
• Male or female patients aged over 18 years, female patients should not be pregnant (menopause or contraception)
• Patients should have given their written consent to take part in the study

Exclusion criteria

• Tracheal lesions and lesions affecting the carina tracheae
• Patients with painful bone metastases (not an absolute criterion since the extent of dyspnea is the decisive element)
• Patients with brain metastases
• Patients having undergone pneumonectomy
• Patients undergoing chemotherapy or radiotherapy or having undergone chemotherapy less than 4 weeks before the procedure or radiotherapy less than 4 weeks before the procedure
• Patients with risk of large vessel erosion or perforation resulting from lesion topography
• In case of allergy to the photosensitizer
• Leukopenia (WBC<2000), Thrombocytopenia (< 100 000), PT > 1.5 normal, Fibrinogen < 2g/l, a PTT > 1.5 ULN (Upper Limit of Normal)
• Renal insufficiency
• Hepatic insufficiency
• Patients having already received 70 Gy on the lesion
• Existing tracheoesophageal or bronchoesophageal fistula
• Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

WST11

Experimental group

Description:

Treatment with WST11-mediated VTP

Treatment:

Drug: WST11